Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06616597 · ClinicalTrials.gov registry record · Phase 2
Trial Targeting Gut Bacterial Androgen Production to Reverse Therapeutic Resistance to Abiraterone in Patients With Metastatic Prostate Cancer
A Phase 2 study of Metastatic Prostate Cancer and Prostate Cancer (Adenocarcinoma), sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 58
- Enrollment target
- 1
- Study location
NCT06616597: Recruiting Phase 2 study of Metastatic Prostate Cancer and Prostate Cancer (Adenocarcinoma), sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
NCT06616597 is a Phase 2 study of Metastatic Prostate Cancer and Prostate Cancer (Adenocarcinoma) that is actively recruiting participants, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 58 participants, below the 185-participant average among 41 other Metastatic Prostate Cancer trials with a reported enrollment target (69% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06616597, a Phase 2 study of Metastatic Prostate Cancer and Prostate Cancer (Adenocarcinoma), is actively recruiting participants, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 58 participants
- Enrollment target
- 1
- Study location
Study Summary
To determine if dexamethasone or dexamethasone plus metronidazole restore sensitivity to abiraterone for the treatment of metastatic prostate cancer.
Primary Outcome
Number of participants with castration resistant prostate cancer who have a ≥ 30% decline in PSA from baseline until 24 weeks.
Conditions Studied
Interventions
- DRUG Dexamethasone
- DRUG Metronidazole
- DRUG Abiraterone acetate
Study Locations (1)
Maryland
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2025-02-13 |
| Est. Completion | 2032-03-30 |
| Phase | Phase 2 |
What NCT06616597 shows while recruiting
NCT06616597 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 58 participants, a relatively small participant target, below the 185-participant average among 41 other Metastatic Prostate Cancer trials with a reported enrollment target (69% lower).
The record links to 2 conditions, with Metastatic Prostate Cancer appearing as the primary indexed condition, and to 3 interventions - of which Dexamethasone is the first listed.
NCT06616597 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT06616597 about?
NCT06616597 is a clinical study titled "Trial Targeting Gut Bacterial Androgen Production to Reverse Therapeutic Resistance to Abiraterone in Patients With Metastatic Prostate Cancer". To determine if dexamethasone or dexamethasone plus metronidazole restore sensitivity to abiraterone for the treatment of metastatic prostate cancer.
What is the current status of trial NCT06616597?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 58 participants. The study started on 2025-02-13. Estimated completion is 2032-03-30.
What conditions does trial NCT06616597 study?
This clinical trial studies the following conditions: Metastatic Prostate Cancer, Prostate Cancer (Adenocarcinoma).
What interventions are being tested in trial NCT06616597?
The interventions under investigation include: Dexamethasone (DRUG), Metronidazole (DRUG), Abiraterone acetate (DRUG).
Who is sponsoring clinical trial NCT06616597?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06616597 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06616597's enrollment target sits among peer trials
58 23rd of 41 higher than 18 of 41 other Metastatic Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metastatic Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Cabazitaxel +/- Carboplatin vs 177Lu-PSMA-617 in Metastatic Castrate-resistant Prostate Cancer
RECRUITING · Phase 2
-
Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate Cancer
RECRUITING · Phase 2
-
A Study of Tarlatamab for People With Prostate Cancer
RECRUITING · Phase 2
-
Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer
RECRUITING · Phase 2
-
High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers
RECRUITING · Phase 2
-
Androgen Receptor Directed Therapy on Cognitive Function in Patients Treated With Darolutamide or Enzalutamide
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03587844 · 58 participants · Phase 2
Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients
- NCT03630991 · 58 participants · Phase 1
Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
- NCT03949855 · 58 participants · Phase 2
Belimumab With Rituximab for Primary Membranous Nephropathy
- NCT04069273 · 58 participants · Phase 2
Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI